Long‐Term Safety and Efficacy of the RTS,S/AS02A Malaria Vaccine in Mozambican Children
The Journal of Infectious Diseases2009Vol. 200(3), pp. 329–336
Citations Over TimeTop 1% of 2009 papers
Jahit Sacarlal, Pedro Aíde, John J. Aponte, Montse Renom, Amanda Leach, Inácio Mandomando, Marc Lievens, Quique Bassat, Sarah Lafuente, Eusébio Macete, Johan Vekemans, Caterina Guinovart, Betuel Sigaúque, Marla Sillman, Jessica Milman, Marie‐Claude Dubois, Marie‐Ange Demoitié, Joëlle Thonnard, Clara Menéndez, W. Ripley Ballou, Joe Cohen, Pedro L. Alonso
Abstract
These results show evidence that RTS,S/AS02A maintained protection during the 45-month surveillance period, and they highlight the feasibility of developing an effective vaccine against malaria. In combination with other malaria-control measures, such a vaccine could greatly contribute to reducing the intolerable global burden of this disease. Trial registration. ClinicalTrials.gov identifiers NCT00197041 and NCT00323622 .
Related Papers
- → Advances and challenges in malaria vaccine development(2010)264 cited
- → Progress towards the development of malaria vaccines(2006)47 cited
- Malaria vaccines: triumphs or tribulations?(1999)
- → Workshop report: Malaria vaccine development in Europe–preparing for the future(2015)5 cited
- → Musings on malaria morbidity and mortality after the new Mosquirix® vaccine(2019)2 cited